Have you seen our new ‘How I treat…’ features? Become a member (it’s free!) and discover the latest advice from fellow clinicians here >>>

ASCO19: enfortumab vedotin produces response in nearly half of patients with advanced urothelial cancer

Written by Sharon Salt, Future Science Group

Enfortumab vedotin (EV) – a new agent that targets nectin-4 – has produced responses in 44% of patients with locally advanced or metastatic forms of urothelial cancer. Although patients were previously treated with platinum chemotherapy and a PD-1 or PD-L1 immune checkpoint inhibitor, their cancer had progressed irrespective of treatment. The results are from a single-arm, Phase II clinical trial of 125 patients, which is being presented at the ASCO 2019 Annual Meeting (31 May–4 June, Chicago, IL, USA). “These Phase II results replicate the Phase I results very closely, which is not often the case in clinical trials,” commented...

To view this content, please register now for access

It's completely free